Urine Sodium Excretion After Tolvaptan Administration Is Dependent Upon Baseline Serum Sodium Levels-Reference-Cited by-同舟云学术

Urine Sodium Excretion After Tolvaptan Administration Is Dependent Upon Baseline Serum Sodium Levels

Published:2014 Issue:2 Volume:55 Page:131-137
ISSN:1349-2365
Container-title:International Heart Journal
language:en
Short-container-title:Int. Heart J.

Author:

Imamura Teruhiko¹,Kinugawa Koichiro²,Minatsuki Shun¹,Muraoka Hironori¹,Kato Naoko²,Inaba Toshiro¹,Maki Hisataka¹,Hatano Masaru¹,Yao Atsushi¹,Komuro Issei¹

Affiliation:

1. Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo

2. Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo

Publisher

International Heart Journal (Japanese Heart Journal)

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/ihj/55/2/55_13-221/_pdf

Reference23 articles.

1. 1. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006; 69: 2124-30. (Review)

2. 2. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011; 25: S57-65.

3. 3. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-5.

4. 4. Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 2013; 61: 169-74.

5. 5. Watanabe K, Dohi K, Sugimoto T, et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol 2012; 60: 462-9.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying the main predictors of urine output in autosomal-dominant polycystic kidney disease (ADPKD) patients taking tolvaptan;International Urology and Nephrology;2023-03-23

2. Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome;CEN Case Reports;2021-04-26

3. Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan;European Journal of Clinical Pharmacology;2020-02-13

4. Vasopressin antagonist efficacy and safety in volume-overloaded critically ill patients: a new therapeutic alternative;European Journal of Hospital Pharmacy;2018-11-10

5. Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria;Heart and Vessels;2017-10-23